Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02888067
Other study ID # 2017-2754
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date July 1, 2017
Est. completion date July 20, 2022

Study information

Verified date October 2023
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether deep neuromuscular blockade provides better surgical conditions than moderate neuromuscular blockade in patients undergoing vocal cord resections requiring jet ventilation.


Description:

To optimize anatomical exposure and to minimize direct manipulation of local lesions endotracheal intubation often is avoided in patients undergoing vocal cord surgery. Instead intermittent so called jet ventilation is carried out by using the Hunsaker Mon-jet tube. The safe conduct of these procedures requires full muscle paralysis. In clinical practice, however, deep neuromuscular blockade (NMB) usually cannot be established for this relatively short surgery (<1h) because of an increased risk of prolonged NMB and postoperative ventilation. The novel neuromuscular blockade reversal agent sugammadex may prove particularly useful in this patient population because it allows fast and reliable reversal of even deep NMB. Deeper muscle paralysis during vocal cord surgery may be associated with better surgical conditions. The purpose of this study is to determine whether deep neuromuscular blockade provides better surgical conditions than moderate neuromuscular blockade in patients undergoing vocal cord resections requiring jet ventilation.


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date July 20, 2022
Est. primary completion date July 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Elective vocal cord resection with an expected length of the procedure longer than 20 minutes and requiring jet ventilation Exclusion Criteria: - Patients younger than 18 years old - Patients unable to give written informed consent - Patients with known or suspected neuromuscular disease - Patients with allergies to medications to be used during anesthesia - Patients with a (family) history of malignant hyperthermia - Patients with renal insufficiency (serum creatinine >2 times normal or a glomerular filtration rate <60 ml/h)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rocuronium bromide 0.5 mg/kg
Moderate neuromuscular blockade with rocuronium bromide
Rocuronium bromide 1.0 mg/kg
Deep neuromuscular blockade with rocuronium bromide
Sugammadex sodium 2 mg/kg
Reversal with sugammadex sodium
Sugammadex sodium 4 mg/kg
Reversal with sugammadex sodium

Locations

Country Name City State
Canada MUHC Montreal Quebec

Sponsors (2)

Lead Sponsor Collaborator
Thomas Schricker Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Five-point surgical rating scale (SRS) Surgical conditions during surgery will be assessed by the surgeon using a five-point surgical rating scale at 10 minutes intervals during surgery, an average period of 50 minutes
Secondary Drug dosages Drugs and dosages used during the study Through study completion, an average of 4 hours
Secondary Time to extubation Time from reversal to optimal extubation conditions (TOF ratio <0.9) During the stay in the operation room, an average of 60 minutes
Secondary Heart rate During the stay in the operation and recovery room, an average of 4 hours
Secondary Arterial blood pressure During the stay in the operation and recovery room, an average of 4 hours
Secondary Oxygen saturation During the stay in the operation and recovery room, an average of 4 hours
Secondary Respiratory rate During the stay in the operation and recovery room, an average of 4 hours
Secondary Body temperature During the stay in the operation and recovery room, an average of 4 hours
Secondary Duration of surgery During the stay in the operation room, an average of 50 minutes
Secondary Duration of post-anesthesia care unit (PACU) stay Time spent in the PACU During the stay in the recovery room, an average of 3 hours
Secondary Pain score On an 11-point numerical rating scale from 0 = no pain, to 10 = most severe pain imaginable at PACU During the stay in the operation and recovery room, an average of 4 hours
Secondary Occurence of nausea/vomiting During the stay in the operation and recovery room, an average of 4 hours
Secondary Sedation On a five-point scale ranging from 0 = normal alertness to 5 = not aroused by a painful stimulus at PACU During the stay in the operation and recovery room, an average of 4 hours
See also
  Status Clinical Trial Phase
Completed NCT04188613 - Use of High-Frequency Jet Ventilation During Percutaneous Tracheostomy N/A
Recruiting NCT06285994 - Complications of High Frequency Jet Ventilation